274 related articles for article (PubMed ID: 10756037)
1. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.
Stittelaar KJ; Wyatt LS; de Swart RL; Vos HW; Groen J; van Amerongen G; van Binnendijk RS; Rozenblatt S; Moss B; Osterhaus AD
J Virol; 2000 May; 74(9):4236-43. PubMed ID: 10756037
[TBL] [Abstract][Full Text] [Related]
2. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles.
Pan CH; Greer CE; Hauer D; Legg HS; Lee EY; Bergen MJ; Lau B; Adams RJ; Polo JM; Griffin DE
J Virol; 2010 Apr; 84(8):3798-807. PubMed ID: 20130066
[TBL] [Abstract][Full Text] [Related]
3. Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates.
Stittelaar KJ; Vos HW; van Amerongen G; Kersten GF; Osterhaus AD; de Swart RL
Vaccine; 2002 Dec; 21(3-4):155-7. PubMed ID: 12450688
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model.
Weidinger G; Ohlmann M; Schlereth B; Sutter G; Niewiesk S
Vaccine; 2001 Apr; 19(20-22):2764-8. PubMed ID: 11282186
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody.
Zhu Yd; Rota P; Wyatt L; Tamin A; Rozenblatt S; Lerche N; Moss B; Bellini W; McChesney M
Virology; 2000 Oct; 276(1):202-13. PubMed ID: 11022008
[TBL] [Abstract][Full Text] [Related]
6. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.
Song MK; Vindurampulle CJ; Capozzo AV; Ulmer J; Polo JM; Pasetti MF; Barry EM; Levine MM
J Virol; 2005 Aug; 79(15):9854-61. PubMed ID: 16014946
[TBL] [Abstract][Full Text] [Related]
7. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies.
van Binnendijk RS; Poelen MC; van Amerongen G; de Vries P; Osterhaus AD
J Infect Dis; 1997 Mar; 175(3):524-32. PubMed ID: 9041322
[TBL] [Abstract][Full Text] [Related]
8. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies.
Schlereth B; Rose JK; Buonocore L; ter Meulen V; Niewiesk S
J Virol; 2000 May; 74(10):4652-7. PubMed ID: 10775601
[TBL] [Abstract][Full Text] [Related]
9. Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins.
Polack FP; Lydy SL; Lee SH; Rota PA; Bellini WJ; Adams RJ; Robinson HL; Griffin DE
Clin Vaccine Immunol; 2013 Feb; 20(2):205-10. PubMed ID: 23239799
[TBL] [Abstract][Full Text] [Related]
10. Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.
Pan CH; Valsamakis A; Colella T; Nair N; Adams RJ; Polack FP; Greer CE; Perri S; Polo JM; Griffin DE
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11581-8. PubMed ID: 16037211
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus.
Oh S; Stegman B; Pendleton CD; Ota MO; Pan CH; Griffin DE; Burke DS; Berzofsky JA
Virology; 2006 Sep; 352(2):390-9. PubMed ID: 16781760
[TBL] [Abstract][Full Text] [Related]
12. A Recombinant Measles Vaccine with Enhanced Resistance to Passive Immunity.
Julik E; Reyes-Del Valle J
Viruses; 2017 Sep; 9(10):. PubMed ID: 28934110
[TBL] [Abstract][Full Text] [Related]
13. Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.
Julik E; Reyes-Del Valle J
J Virol; 2016 Jun; 90(11):5270-5279. PubMed ID: 26984727
[TBL] [Abstract][Full Text] [Related]
14. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge.
Taylor J; Pincus S; Tartaglia J; Richardson C; Alkhatib G; Briedis D; Appel M; Norton E; Paoletti E
J Virol; 1991 Aug; 65(8):4263-74. PubMed ID: 1830113
[TBL] [Abstract][Full Text] [Related]
15. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus.
Pan CH; Jimenez GS; Nair N; Wei Q; Adams RJ; Polack FP; Rolland A; Vilalta A; Griffin DE
Clin Vaccine Immunol; 2008 Aug; 15(8):1214-21. PubMed ID: 18524884
[TBL] [Abstract][Full Text] [Related]
16. Passively administered antibody suppresses the induction of measles virus antibodies by vaccinia-measles recombinant viruses.
Galletti R; Beauverger P; Wild TF
Vaccine; 1995 Feb; 13(2):197-201. PubMed ID: 7625116
[TBL] [Abstract][Full Text] [Related]
17. Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.
Lin WH; Vilalta A; Adams RJ; Rolland A; Sullivan SM; Griffin DE
J Virol; 2013 Jun; 87(12):6560-8. PubMed ID: 23552419
[TBL] [Abstract][Full Text] [Related]
18. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats.
Pasetti MF; Barry EM; Losonsky G; Singh M; Medina-Moreno SM; Polo JM; Ulmer J; Robinson H; Sztein MB; Levine MM
J Virol; 2003 May; 77(9):5209-17. PubMed ID: 12692223
[TBL] [Abstract][Full Text] [Related]
19. Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies.
Muñoz-Alía MA; Casasnovas JM; Celma ML; Carabaña J; Liton PB; Fernandez-Muñoz R
Virus Res; 2017 May; 236():30-43. PubMed ID: 28465158
[TBL] [Abstract][Full Text] [Related]
20. Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose.
Schlereth B; Buonocore L; Tietz A; Meulen VT; Rose JK; Niewiesk S
J Gen Virol; 2003 Aug; 84(Pt 8):2145-2151. PubMed ID: 12867646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
